FI934751L - Extracellulaera matrisreceptorligander som modulerar leukocytfunktioner - Google Patents

Extracellulaera matrisreceptorligander som modulerar leukocytfunktioner Download PDF

Info

Publication number
FI934751L
FI934751L FI934751A FI934751A FI934751L FI 934751 L FI934751 L FI 934751L FI 934751 A FI934751 A FI 934751A FI 934751 A FI934751 A FI 934751A FI 934751 L FI934751 L FI 934751L
Authority
FI
Finland
Prior art keywords
modulerar
matrisreceptorligander
leukikotfunktioner
extracellulaera
som
Prior art date
Application number
FI934751A
Other languages
English (en)
Other versions
FI934751A7 (fi
FI934751A0 (fi
Inventor
Alejandro A Aruffo
N Jan Chalupny
John Marken
Jeffrey A Ledbetter
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of FI934751A0 publication Critical patent/FI934751A0/fi
Publication of FI934751A7 publication Critical patent/FI934751A7/fi
Publication of FI934751L publication Critical patent/FI934751L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FI934751A 1992-10-30 1993-10-27 Extracellulaera matrisreceptorligander som modulerar leukocytfunktioner FI934751L (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96970092A 1992-10-30 1992-10-30

Publications (3)

Publication Number Publication Date
FI934751A0 FI934751A0 (fi) 1993-10-27
FI934751A7 FI934751A7 (fi) 1994-05-01
FI934751L true FI934751L (fi) 1994-05-01

Family

ID=25515876

Family Applications (1)

Application Number Title Priority Date Filing Date
FI934751A FI934751L (fi) 1992-10-30 1993-10-27 Extracellulaera matrisreceptorligander som modulerar leukocytfunktioner

Country Status (8)

Country Link
EP (1) EP0595659A3 (fi)
JP (1) JPH072899A (fi)
AU (1) AU5034493A (fi)
CA (1) CA2109398A1 (fi)
FI (1) FI934751L (fi)
IL (1) IL107432A0 (fi)
MX (1) MX9306682A (fi)
NO (1) NO933860L (fi)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5246113A (en) * 1992-02-11 1993-09-21 Riverwood International Corporation Carrier for stacked articles
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
HUP9904697A3 (en) 1996-10-11 2001-06-28 Bristol Myers Squibb Company P Methods and compositions for immunomodulation
CA2308017A1 (en) 1997-10-30 1999-05-14 Erik S. Falck-Pedersen A method of inhibiting an immune response to a recombinant vector
US9309320B2 (en) 2006-12-28 2016-04-12 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
SI2874659T1 (sl) 2012-07-18 2016-11-30 Apogenix Ag Inhibitorji signalizirane poti CD95 za zdravljenje MDS
JP2014184804A (ja) 2013-03-22 2014-10-02 Toyota Motor Corp 車両用動力伝達装置の制御装置
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
WO2017044752A1 (en) * 2015-09-10 2017-03-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
CA3134144A1 (en) 2019-03-29 2020-10-08 Myst Therapeutics, Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods
IL293350A (en) 2019-11-27 2022-07-01 Myst Therapeutics Llc Method of producing tumor-reactive t cell composition using modulatory agents
CN115427438A (zh) 2020-02-27 2022-12-02 迈斯特治疗公司 肿瘤反应性t细胞的离体富集和扩增的方法及其相关组合物
WO2026044087A1 (en) 2024-08-21 2026-02-26 Shape Therapeutics Inc. Increased cellular stability for aav production

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3149289A (en) * 1988-03-18 1989-09-21 Rockefeller University, The Method and agent for inhibiting the binding of human polymorphonuclear leukocytes to endothelium and compositions therefor
US5057604A (en) * 1988-08-03 1991-10-15 Washington University Novel monoclonal antibodies
US5204445A (en) * 1988-10-03 1993-04-20 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5169930A (en) * 1990-01-05 1992-12-08 La Jolla Cancer Research Foundation Fibronectin receptor
WO1991019511A1 (en) * 1990-06-18 1991-12-26 The General Hospital Corporation CONTROLLING CELLULAR IMMUNE/INFLAMMATORY RESPONSES WITH β2 INTEGRINS

Also Published As

Publication number Publication date
NO933860D0 (no) 1993-10-27
IL107432A0 (en) 1994-01-25
AU5034493A (en) 1994-05-12
FI934751A7 (fi) 1994-05-01
MX9306682A (es) 1994-04-29
CA2109398A1 (en) 1994-05-01
JPH072899A (ja) 1995-01-06
FI934751A0 (fi) 1993-10-27
EP0595659A3 (en) 1995-01-11
NO933860L (no) 1994-05-02
EP0595659A2 (en) 1994-05-04

Similar Documents

Publication Publication Date Title
FI935058L (fi) Foer antitumoerbehandling avsedda rekombinant-adenovirus som uttrycker cytokiner
FI931229A0 (fi) Som glanspigment laempade blandningar
FI934750A7 (fi) Kommunikationsfoerfarande i TDMA-cellulaermobilradiosystem som anvaender frekvenshoppning
FI930995A7 (fi) Elektronisk spaerrcylinder som inkopplas med stiftkoppling
FI934568A0 (fi) Hydrofobisitet som aostadkommits med metalljonaktivering
FI931069A0 (fi) Kolloidalt rostat kaffe som aromatiseringsprodukt
FI924091A7 (fi) Autoriseringsprotokoll som foersiktighetshjaelpmedel
FI933167A0 (fi) N-alkylkinuklidiniumsalter som substans-p antagonister
FI921675L (fi) En detergentsammansaettning innehaollande polyimidbiopolymer som blir hydrolyserad i tvaettningsvatten
FI921556L (fi) Plasttillslutning som visar otillboerlig anvaendning
FI921182L (fi) Velangummi som snabbt hydratiseras
FI933560A7 (fi) Radiotelefonsystem som anvaender en flerabonnentenhet
FI935944L (fi) Pyratsolopyrimidin- samt pyrimidinylbisfosfonestrar som anti- inflammatorer
FI925330L (fi) Substituerade fenylfenoler som leukotrienantagonister
FI933022A0 (fi) Radiosystem som bildar en traodloes lokalslinga
FI934751L (fi) Extracellulaera matrisreceptorligander som modulerar leukocytfunktioner
FI930722L (fi) Foerfarande foer framstaellning av polymerer som innehaoller ammoniumgrupper
FI934764A0 (fi) Anordning som hindrar krympning av kabelisolering
FI932284L (fi) Kalciumkanaler blockerande polypeptider som haerstammar fraon filistata hibernalis
FI930342A0 (fi) Pentapeptider som reglerar immun- och nervsystem
FI930219L (fi) Anvaendning av reaktionsblandningar som gjutbara massor
FI935867L (fi) Tetrahydrobensazepinderivat som inhibiterar lipoxigenas
FI935826A0 (fi) Kallsmoerjmedel med delvis neutraliserade fosforsyraestrar som EP-tillsatsaemnen
FI930721L (fi) Foerfarande foer framstaellning av polymerer som innehaoller aminogrupper
FI554U1 (fi) Reklam som aendrar faerg

Legal Events

Date Code Title Description
FD Application lapsed